Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;18(4):21.
doi: 10.1007/s11912-016-0509-x.

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Claire F Friedman  1 , Michael A Postow  2
Affiliations
Review

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Claire F Friedman et al. Curr Oncol Rep. 2016 Apr.

Abstract

The immune system plays an essential role in the surveillance and eradication of neoplastic cells. This interaction is modulated via immunologic regulators (checkpoints). Antibodies that block the checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death protein 1 pathway (PD1/PD-L1) have demonstrated efficacy in a number of malignancies. However, response rates are variable, and administration of these antibodies can be associated with immune-related adverse events. Therefore, researchers are engaged in an effort to discover biomarkers that may predict response to these agents. This review focuses on potential blood and tumor-based biomarkers that have been assessed in patients treated with these checkpoint-blocking antibodies.

Keywords: Biomarkers; CTLA-4; Checkpoint blockade; Immunotherapy; Ipilimumab; Melanoma; Neoantigens; Nivolumab; PD-1; PD-L1; Pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Claire F. Friedman has received travel reimbursement from Bristol-Myers Squibb. Michael A. Postow has received research funding through a grant from Bristol-Myers Squibb and has received honoraria from Merck, compensation from Caladrius, and Amgen for service on advisory boards, and honoraria and travel reimbursement from Bristol-Myers Squibb.

References

    1. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. - PubMed
    1. Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17. - PubMed
    1. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. - PubMed
    1. Wolchok JD, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. - PubMed
    1. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. - PubMed

Publication types

MeSH terms